Spyre Therapeutics has announced promising results from the Phase 2 SKYLINE trial of SPY001, an investigational anti-α4β7 antibody designed to treat moderate-to-severe ulcerative colitis (UC). The trial’s Part A demonstrated a statistically significant reduction of 9.2 points in the Robart’s Histopathology Index (RHI) score at Week 12 (p<0.0001). Additionally, secondary endpoints showed 40% clinical remission and 51% endoscopic improvement, indicating strong therapeutic potential.

These findings underscore SPY001’s potential to surpass existing treatments, such as vedolizumab, by enhancing target coverage and induction dosing through an extended half-life. The safety profile of SPY001 aligns with the α4β7 class, with a low incidence of treatment-emergent adverse events, suggesting a favorable risk-benefit ratio. As recruitment for Part B of the trial progresses, which includes both monotherapy and combination cohorts, the data from Part A could inform future strategies for combination therapies with Spyre’s other investigational antibodies, SPY002 and SPY003.

The implications of these results are significant for the field of IBD therapy. SPY001’s performance not only supports its candidacy as a best-in-class treatment option but also positions it as a potential backbone for combination therapies, which may enhance treatment efficacy and patient outcomes. As the trial moves into its next phase, the anticipated proof-of-concept data for the combinations could reshape current research paradigms and accelerate the development timelines for novel IBD therapies.

Source: globenewswire.com